Home Companies EpiBiologics COMPANY
Clinical Phase 1
Keywords: antibody oncology immunology Head and Neck Cancer Epidermal Growth Factor Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Gene Mutation Non Small Cell Non Small Cell Lung Non Small Cell Lung Cancer Head and Neck Head and Neck Squamous Cell Cancer Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma HNSCC NSCLC (Non-small Cell Lung Cancer) HNSCC EPI-326 Show all 17 keywords
Location: San Mateo, CA · source · Oct 15, 2026
Profile checked Oct 10, 2026
At a glance HQ San Mateo, CA source Stage Clinical Phase 1 Latest trial 1: A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC (Mar 31, 2026) source Raises and deals from press releases Raise Series B · $107M · announced Jan 8, 2026 Company release ↗ Source quote Jan 8, 2026 · Company release ↗ “— EpiBiologics , a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson” Raises announced in these releases: $107M disclosed.
From the company’s own releases; this list is partial. All raises and deals
Timeline Mar 31, 2026 Trial start 1: A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC source ↗ Jan 8, 2026 Raise Private equity round — Series B: $107M (total, as published), announced Jan 8, 2026. Source: company's own press page. source ↗ Jan 8, 2026 Raise Series B · $107M source ↗ Upcoming milestones 2029-07 (ESTIMATED) · 1 · A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC · NCT07462377 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $107.0M. Last 2 years.
Jan 8, 2026 Private equity round — Series B: $107M (total, as published), announced Jan 8, 2026. Source: company's own press page. source ↗ Clinical trials (lead sponsor) 1 Record Title Phase Status Start Primary completion NCT07462377 A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC 1 Recruiting Mar 31, 2026 2029-07 (estimated)
